Funding Opportunity PAR-25-050 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to support rigorous analytical validation of method(s) used for measuring biomarkers for neurological and neuromuscular disorders for use in clinical trials or clinical practice. Applicants must justify the unmet need for the biomarker(s) and measurement methods and specify one or two context(s) of use for the biomarker(s). Activities supported include optimizing and evaluating the accuracy, precision, reportable range, and analytical sensitivity and specificity of the detection method across multiple sites and operators and establishing reference intervals and quality control procedures. Multi-site applications are expected but not required.

Funding Opportunity PAR-25-055 from the NIH Guide for Grants and Contracts. The purpose of this Program Announcement (PAR) is to enable clinical validation of strong candidate biomarkers for neurological diseases and conditions. Specifically, the goal of this PAR is to enable the rigorous validation of biomarker measurements within the clinical population of interest to establish the positive and negative predictive values of the candidate biomarker consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed and analytically validated, and 3) the research and/or clinical need and potential context of use has been identified.

Notice NOT-AG-24-010 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-25-020 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that help recruit individuals with specific specialty or disciplinary backgrounds to research careers in biomedical, behavioral and clinical sciences.

Funding Opportunity RFA-CA-25-009 from the NIH Guide for Grants and Contracts. Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to advance the science of scale-up and sustainment of lung cancer screening (LCS) for populations at high risk for lung cancer. This NOFO will support studies that will identify the most effective implementation strategies for scaling-up and sustaining the delivery of LCS across a range of clinical care settings and diverse populations at high risk for lung cancer. This NOFO will use the UG3/UH3 phased cooperative agreement mechanism. The UG3 phase will support preparatory activities for the scale-up and sustainment trial. The UH3 phase will support the scale-up and sustainment trial.

Notice NOT-DA-24-046 from the NIH Guide for Grants and Contracts

Notice NOT-CA-24-109 from the NIH Guide for Grants and Contracts

Funding Opportunity PA-25-080 from the NIH Guide for Grants and Contracts. The purpose of the NIH Research Conference Grant (R13) is to support high quality conferences that are relevant to the public health and to the scientific mission of the participating Institutes and Centers.

Notice NOT-NS-24-132 from the NIH Guide for Grants and Contracts

Notice NOT-GM-24-053 from the NIH Guide for Grants and Contracts

Notice NOT-GM-24-052 from the NIH Guide for Grants and Contracts

Notice NOT-GM-24-051 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-CA-25-013 from the NIH Guide for Grants and Contracts. The overall goal of this UG3/UH3 Exploratory/Developmental phased initiative is to support the discovery and development of novel natural products that are safe, nontoxic, and efficacious for cancer interception and prevention. 1. Purpose of UG3: Select clinically relevant targets and develop and validate assays for bioactivity as well as toxicity screening 2. Purpose of UH3 phase: Screening libraries, structure elucidation, full-scale characterization, efficacy testing, and development of the screened agents.

Notice NOT-DA-24-047 from the NIH Guide for Grants and Contracts

Notice NOT-OD-25-005 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-24-294 from the NIH Guide for Grants and Contracts. Reissue PAR-21-233 - The Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics) provides support for biologic-based therapeutic discovery and development, from lead optimization through phase I clinical testing. This Funding Opportunity Announcement (FOA) supports preclinical discovery and development of potential therapeutic Biotechnology Products and Biologics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies). Applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in manufacturing, scaling, pharmacokinetics, toxicology, and Phase I clinical testing. BPN-Biologics awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN-Biologics contractors (and thereby control the patent prosecution and licensing negotiations) for biotherapeutic candidates developed in this program.

Funding Opportunity PAR-24-293 from the NIH Guide for Grants and Contracts. The Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics) provides support for biologic-based therapeutic discovery and development, from lead optimization through phase I clinical testing. This Funding Opportunity Announcement (FOA) supports preclinical discovery and development of potential therapeutic Biotechnology Products and Biologics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies). Applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in manufacturing, scaling, pharmacokinetics, toxicology, and Phase I clinical testing. BPN-Biologics awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN-Biologics contractors (and thereby control the patent prosecution and licensing negotiations) for biotherapeutic candidates developed in this program.

Notice NOT-NR-25-001 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-25-061 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) invites applications from eligible academic and research institutions to apply for funding to modernize existing or construct new biomedical research facilities. Applications will be accepted from public and private nonprofit institutions of higher education, as well as from non-profit research organizations. Applications from both research-intensive institutions and Institutions of Emerging Excellence(IEE) in biomedical research from all geographic regions in the nation are strongly encouraged. NIH recognizes the importance of all institutions of higher learning in contributing to the nations research capacity from either research-intensive or low-resourced institutions. The goal of this NOFO is to modernize biomedical research infrastructure to strengthen biomedical research programs. Each project is expected to produce substantial long-term improvements to the institutional research infrastructure. Intended projects are the construction or modernization of core facilities and the development of other shared research infrastructure serving an institution-wide research community with broad impact on biomedical research.

Notice NOT-GM-24-055 from the NIH Guide for Grants and Contracts